🇺🇸 FDA
Patent

US 11319539

Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

granted A61KA61K31/713A61K47/14

Quick answer

US patent 11319539 (Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/713, A61K47/14, A61K9/0019, A61P